- Home
- APVO vs RANI Comparison
APVO vs RANI Comparison
Compare APVO & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- RANI
- Stock Information
- Founded
- APVO 2016
- RANI 2012
- Country
- APVO United States
- RANI United States
- Employees
- APVO N/A
- RANI N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- APVO Health Care
- RANI Health Care
- Exchange
- APVO Nasdaq
- RANI Nasdaq
- Market Cap
- APVO 21.7M
- RANI 24.2M
- IPO Year
- APVO N/A
- RANI 2021
- Fundamental
- Price
- APVO $1.09
- RANI $1.56
- Analyst Decision
- APVO
- RANI Strong Buy
- Analyst Count
- APVO 0
- RANI 6
- Target Price
- APVO N/A
- RANI $8.67
- AVG Volume (30 Days)
- APVO 757.7K
- RANI 11.6M
- Earning Date
- APVO 11-06-2025
- RANI 11-06-2025
- Dividend Yield
- APVO N/A
- RANI N/A
- EPS Growth
- APVO N/A
- RANI N/A
- EPS
- APVO N/A
- RANI N/A
- Revenue
- APVO N/A
- RANI $1,200,000.00
- Revenue This Year
- APVO N/A
- RANI N/A
- Revenue Next Year
- APVO N/A
- RANI N/A
- P/E Ratio
- APVO N/A
- RANI N/A
- Revenue Growth
- APVO N/A
- RANI N/A
- 52 Week Low
- APVO $1.07
- RANI $0.39
- 52 Week High
- APVO $298.00
- RANI $3.87
- Technical
- Relative Strength Index (RSI)
- APVO 27.92
- RANI 45.86
- Support Level
- APVO $1.39
- RANI $1.79
- Resistance Level
- APVO $1.54
- RANI $1.99
- Average True Range (ATR)
- APVO 0.09
- RANI 0.30
- MACD
- APVO -0.03
- RANI -0.10
- Stochastic Oscillator
- APVO 3.06
- RANI 0.18
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.